Mitchell Elliott, MD, UHN Princess Margaret Cancer Centre, Toronto, Canada, discusses the preclinical evaluation of ARB-1-6, a sortilin (SORT1) targeted peptide conjugated to MMAE, in breast cancer patient-derived xenografts (PDX). ARB-1-6 demonstrated significant antitumor activity, with complete response observed in a majority of breast cancer models. Notably, it exhibited efficacy in a PDX derived from a patient resistant to a TROP2 antibody drug conjugate. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.